**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 70-year-old woman developed acute generalised exanthematous pustulosis (AGEP) with erythema multiforme-like lesions following off-label treatment with hydroxychloroquine and lopinavir/ritonavir for SARS-CoV-2 pneumonia \[*routes not stated*\].

The woman was admitted to the clinic due to rapid onset of a diffuse, pruritic pustular eruption. Three weeks before, she had received off-label treatment with lopinavir/ritonavir 200/50mg 2 tablets and hydroxychloroquine 200mg twice a day for 10 days for SARS-CoV-2 pneumonia. Three days after completion of treatment course, she developed the onset of a skin eruption on the upper arms, which rapidly spread over her trunk.

The woman was therefore treated with prednisone. After 7 days, she consult the emergency department due to the worsening of the skin eruption. Physical examination showed a widespread eruption on an erythematous--oedematous base along with scattered pinhead-sized pustules and scales, involving her face, upper limbs and trunk. Targetoid lesions studded with small pustules were observed in a symmetric pattern over her buttocks, legs and thighs. Mucous membranes, soles and palms were spared. A skin biopsy taken from the thigh showed a subcorneal pustule with mild focal acanthosis and spongiosis, sparse keratinocyte necrosis, neutrophilic exocytosis and a perivascular lymphocytic infiltrate with rare neutrophils and eosinophils. All the findings were consistent with AGEP. She was suggested to taper prednisone gradually within 30 days with a slow but progressive resolution occurred. Hydroxychloroquine-induced AGEP accompanied by erythema multiforme-like lesions was thus considered. Additionally, a contributory role of lopinavir/ritonavir in development of AGEP could not be ruled out.
